Regenerative Biologics
in Neurological
Medicine

Cerebral palsy — nonprogressive motor disability arising from early brain injury — affects approximately 1 in 500 children and generates significant caregiver and healthcare burden. Unlike HIE, the treatment window is not acuity-dependent — neuroplasticity in children’s developing brains provides an extended window for biologic-supported functional improvement across the first decade of life.

The Duke cerebral palsy program spanning 2010–2023 has treated over 200 children with autologous CB and established that: (1) ≥2 × 10⁷ TNC/kg is the minimum effective dose; (2) GMFCS I–III patients (less severe) show the largest functional gains; (3) benefits are most pronounced on motor function when combined with intensive physical therapy. A Phase II trial (Sun JM, 2017) did not reach significance on the primary endpoint with lower doses — the lesson that dose matters in CB neurological applications more than perhaps any other biologic indication.

Ischemic stroke is the largest unmet neurological recovery need in adults — affecting 12.2 million people annually with only rtPA and mechanical thrombectomy as disease-modifying acute interventions, and no approved therapies for chronic deficits. The biologic opportunity spans from acute neuroprotection (within hours, targeting penumbral rescue) to subacute immunomodulation (days to weeks, targeting neuroinflammation resolution) to chronic neuroplasticity support (weeks to months, targeting circuit reorganization).

Phase I safety data for IV cord blood MNCs (Laskowitz 2015) and multiple MSC preparations supports favorable short-term safety in stroke. The STEMTRA Phase IIb multicenter RCT (NCT02969876) is the most advanced stroke biologic trial, evaluating IV allogeneic CB MNCs vs. placebo with mRS as the primary endpoint. Timing data suggests the subacute window (24 hours to 7 days post-stroke) is the optimal intervention point for current biologic protocols, after acute care has been completed.

ALS — relentless progressive degeneration of upper and lower motor neurons producing paralysis and respiratory failure — has no curative treatment. Riluzole, edaravone, and AMX0035 modestly slow progression; biologic therapies aim to augment motor neuron survival through paracrine neurotrophic support delivered to the spinal cord via intrathecal administration.

The Israeli BrainStorm Cell Therapeutics MSC-NTF program (NurOwn) has produced the most Phase II data for MSC therapy in ALS. The Phase II/III trial (Petrou 2022) demonstrated safety and a significant ALSFRS-R slope reduction in the high-dose group. A subsequent Phase III trial (NCT03280056) did not meet its primary endpoint in the overall population but showed significant benefit in a rapidly-progressing biomarker-stratified subgroup — a pattern consistent across neurological biologic trials where patient selection by biological markers (CSF NfL, inflammatory markers) significantly affects response rates.

MS biologic therapy operates in two mechanistic contexts: hematopoietic stem cell transplantation (HSCT) — using chemotherapy conditioning followed by autologous HSC rescue to “reset” the dysregulated immune system — and mesenchymal cell therapy targeting remyelination and neuroprotection. These are distinct approaches with different evidence bases and patient populations.

Autologous HSCT for relapsing-remitting MS has Phase II/III RCT support (MIST trial, NEJM 2019) showing significantly better relapse-free survival vs. disease-modifying therapy alone, but with a ~0.3% mortality risk from the conditioning regimen limiting its use to aggressive RRMS patients. MSC therapy for progressive MS (no effective DMT options exist) is the more immediately relevant biologic frontier — targeting remyelination and neuroprotection rather than immune reset, with the NurOwn biomarker findings providing a roadmap for patient selection optimization.

Traumatic brain injury — affecting 69 million people annually — produces primary mechanical injury (contusion, diffuse axonal injury) followed by a secondary injury cascade of excitotoxicity, neuroinflammation, and programmed cell death that unfolds over hours to days. This secondary cascade is the biologic target: intervening with neuroprotective and anti-inflammatory biologics within the post-injury window (6 hours to 7 days) may reduce secondary injury volume and improve long-term function.

IV MSC therapy in moderate-to-severe TBI has been evaluated in Phase I/II trials showing safety and preliminary cognitive function signals. Autologous cord blood therapy for pediatric TBI is in early clinical evaluation. A key limitation in TBI biologic trials is the marked heterogeneity of injury type, location, and severity across enrolled patients — a challenge that biomarker stratification (serum GFAP, UCH-L1, NfL) is beginning to address in current trial designs.

Spinal cord injury (SCI) — affecting 250,000–500,000 people annually — combines the CNS’s intrinsic regeneration limitations with the physical barrier of the glial scar and myelin-associated inhibitors, making it one of the most biologically challenging injury targets. The subacute window (3–12 weeks post-injury) before scar consolidation is the primary biologic intervention opportunity.

Both intrathecal and IV cord blood MNC and MSC delivery have been evaluated in Phase I/II SCI trials, with the pooled meta-analysis (Yao 2018) finding a significant ASIA conversion benefit in the subacute phase. Biologic mechanisms include anti-apoptotic protection for surviving motor neurons, axonal sprouting support via BDNF/NGF, reduction of glial scar formation through TSG-6, and — in preclinical remyelination data — OPC-mediated myelin repair. Treatment beyond 1 year post-injury shows no benefit in current evidence, consistent with glial scar consolidation eliminating the biologic opportunity.

Peripheral nerve conditions — carpal tunnel syndrome, cubital tunnel syndrome, ulnar neuropathy, and diabetic peripheral neuropathy — represent the most clinically accessible neurological biologic targets because: (1) peripheral nerves regenerate (unlike CNS neurons); (2) ultrasound-guided perineural injection is a well-established procedural platform; (3) nerve conduction velocity provides an objective, reproducible biological outcome measure; and (4) PRP’s NGF and BDNF content directly supports Schwann cell activity and axonal regeneration.

For carpal tunnel syndrome, the meta-analysis (Lin 2020) demonstrates superior nerve conduction velocity improvement with PRP vs. corticosteroid at 6 months — a structural biological finding that distinguishes PRP’s mechanism from symptom suppression. For diabetic peripheral neuropathy, PRP delivers growth factors to the endoneurial vascular bed that are reduced in diabetic nerve, with clinical series reporting significant NCS and symptom score improvements in DPN unresponsive to conventional medical management.